![Therapeutic vaccination for treatment of chronic hepatitis B - Cargill - 2021 - Clinical & Experimental Immunology - Wiley Online Library Therapeutic vaccination for treatment of chronic hepatitis B - Cargill - 2021 - Clinical & Experimental Immunology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/4cb6d32c-0061-4f4b-b2de-6e5d121f0b8c/cei13614-fig-0002-m.jpg)
Therapeutic vaccination for treatment of chronic hepatitis B - Cargill - 2021 - Clinical & Experimental Immunology - Wiley Online Library
![Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 | MMWR Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 | MMWR](https://www.cdc.gov/mmwr/volumes/72/rr/social-media/rr7201a1_HepatitisB_IMAGE_10Mar2023_1200x675-v2-medium.jpg?_=10974)
Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 | MMWR
Hepatitis Australia - Sadly, there is no vaccine for hepatitis C. However, there are preventive vaccines available for hepatitis B and hepatitis A. Hep C can be cured with new treatments available.
![SmartVac - Next Generation Viral Hepatitis B and C vaccine development in plantsand algae using advanced biotechnological tools - Nibio SmartVac - Next Generation Viral Hepatitis B and C vaccine development in plantsand algae using advanced biotechnological tools - Nibio](https://www.nibio.no/en/projects/smartvac-next-generation-viral-hepatitis-b-and-c-vaccine-development-in-plants-and-algae-using-advanced-biotechnological-tools/_/image/30ad6d57-5857-473c-b746-fb1fb188c0e1:e32b9e46af29f022e818cee6972b30ff695dadd2/max-1280/HCV%20talk%20Biotechnology%20Havana%202017%20Dec%206,%202017-bilde.jpg?quality=60)
SmartVac - Next Generation Viral Hepatitis B and C vaccine development in plantsand algae using advanced biotechnological tools - Nibio
![Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial - The Lancet Infectious Diseases Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/91dbf75b-2288-4086-9df9-adddee7ae55e/gr1_lrg.jpg)